Galapagos NV (GLPG) Gets a Buy Rating from Cowen & Co.

By Carrie Williams

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Galapagos NV (GLPGResearch Report) today. The company’s shares opened today at $98.18.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 4.8% and a 46.4% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals Inc, Allogene Therapeutics Inc, and Voyager Therapeutics Inc.

Galapagos NV has an analyst consensus of Strong Buy, with a price target consensus of $135.

See today’s analyst top recommended stocks >>

The company has a one-year high of $122.28 and a one-year low of $85. Currently, Galapagos NV has an average volume of 95.06K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. It operates through the Research and Development and Fee-for-Services segment. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.